Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 190

2.

CEA - a predictor for pathologic complete response after neoadjuvant therapy for rectal cancer.

Wallin U, Rothenberger D, Lowry A, Luepker R, Mellgren A.

Dis Colon Rectum. 2013 Jul;56(7):859-68. doi: 10.1097/DCR.0b013e31828e5a72.

PMID:
23739192
3.

Reappraisal of pretreatment carcinoembryonic antigen in patients with rectal cancer receiving preoperative chemoradiotherapy.

Yeo SG, Kim DY, Chang HJ, Park JW, Oh JH, Kim BC, Baek JY, Kim SY, Kim TH.

Tumori. 2013 Jan-Feb;99(1):93-9. doi: 10.1700/1248.13795.

PMID:
23549007
4.

The use of molecular markers as a method to predict the response to neoadjuvant therapy for advanced stage rectal adenocarcinoma.

Edden Y, Wexner SD, Berho M.

Colorectal Dis. 2012 May;14(5):555-61. doi: 10.1111/j.1463-1318.2011.02697.x.

PMID:
21689364
5.
6.

Predictors of sensitivity to preoperative chemoradiotherapy of rectal adenocarcinoma.

Yan H, Wang R, Zhu K, Zhao W, Jiang S, Feng R, Xu X, Meng X, Sun H, Zhang H, Mu D, Xu Z.

Tumori. 2011 Nov-Dec;97(6):717-23. doi: 10.1700/1018.11087.

7.

Prevalence and significance of anaemia in patients receiving long-course neoadjuvant chemoradiotherapy for rectal carcinoma.

Walter CJ, Bell LT, Parsons SR, Jackson C, Borley NR, Wheeler JM.

Colorectal Dis. 2013 Jan;15(1):52-6. doi: 10.1111/j.1463-1318.2012.03112.x.

PMID:
22642876
8.

Can pathological complete response in the primary tumour following pre-operative pelvic chemoradiotherapy for T3-T4 rectal cancer predict for sterilisation of pelvic lymph nodes, a low risk of local recurrence and the appropriateness of local excision?

Hughes R, Glynne-Jones R, Grainger J, Richman P, Makris A, Harrison M, Ashford R, Harrison RA, Livingstone JI, McDonald PJ, Meyrick Thomas J, Mitchell IC, Northover JM, Phillips R, Wallace M, Windsor A, Novell JR.

Int J Colorectal Dis. 2006 Jan;21(1):11-7. Epub 2005 Apr 30.

PMID:
15864605
9.

Neoadjuvant therapy for rectal cancer: improved tumor response, local recurrence, and overall survival in nonanemic patients.

Box B, Lindsey I, Wheeler JM, Warren BF, Cunningham C, George BD, Mortensen NJ, Jones AC.

Dis Colon Rectum. 2005 Jun;48(6):1153-60.

PMID:
15868236
10.

The prognostic value of lymph node metastases and tumour regression grade in rectal cancer patients treated with long-course preoperative chemoradiotherapy.

Lindebjerg J, Spindler KL, Ploen J, Jakobsen A.

Colorectal Dis. 2009 Mar;11(3):264-9. doi: 10.1111/j.1463-1318.2008.01599.x. Epub 2008 Jun 20.

PMID:
18573119
11.

Rsf-1 expression in rectal cancer: with special emphasis on the independent prognostic value after neoadjuvant chemoradiation.

Lin CY, Tian YF, Wu LC, Chen LT, Lin LC, Hsing CH, Lee SW, Sheu MJ, Lee HH, Wang YH, Shiue YL, Wu WR, Huang HY, Hsu HP, Li CF, Chen SH.

J Clin Pathol. 2012 Aug;65(8):687-92. doi: 10.1136/jclinpath-2012-200786. Epub 2012 May 8.

PMID:
22569540
12.

Watch and wait approach following extended neoadjuvant chemoradiation for distal rectal cancer: are we getting closer to anal cancer management?

Habr-Gama A, Sabbaga J, Gama-Rodrigues J, São Julião GP, Proscurshim I, Bailão Aguilar P, Nadalin W, Perez RO.

Dis Colon Rectum. 2013 Oct;56(10):1109-17. doi: 10.1097/DCR.0b013e3182a25c4e.

PMID:
24022527
13.

Combination of differentiation and T stage can predict unresponsiveness to neoadjuvant therapy for rectal cancer.

Qiu HZ, Wu B, Xiao Y, Lin GL.

Colorectal Dis. 2011 Dec;13(12):1353-60. doi: 10.1111/j.1463-1318.2011.02570.x.

PMID:
21689282
14.

Pilot study of intense neoadjuvant chemoradiotherapy for locally advanced rectal cancer: retrospective review of a phase II study.

Xu BH, Chi P, Guo JH, Guan GX, Tang TL, Yang YH, Chen MQ, Song JY, Feng CY.

Tumori. 2014 Mar-Apr;100(2):149-57. doi: 10.1700/1491.16399.

15.

Neoadjuvant conformal chemoradiation with induction chemotherapy for rectal adenocarcinoma. A prospective observational study.

Fekete Z, Muntean AS, Hica Ş, Rancea A, Resiga L, Csutak C, Todor N, Nagy VM.

J Gastrointestin Liver Dis. 2014 Jun;23(2):171-8.

16.

Concomitant boost IMRT-based neoadjuvant chemoradiotherapy for clinical stage II/III rectal adenocarcinoma: results of a phase II study.

Zhu J, Liu F, Gu W, Lian P, Sheng W, Xu J, Cai G, Shi D, Cai S, Zhang Z.

Radiat Oncol. 2014 Mar 7;9:70. doi: 10.1186/1748-717X-9-70.

17.

Clinical tumour size and nodal status predict pathologic complete response following neoadjuvant chemoradiotherapy for rectal cancer.

Garland ML, Vather R, Bunkley N, Pearse M, Bissett IP.

Int J Colorectal Dis. 2014 Mar;29(3):301-7. doi: 10.1007/s00384-013-1821-7. Epub 2014 Jan 14.

PMID:
24420737
19.

Long-term outcome of patients with complete pathologic response after neoadjuvant chemoradiation for cT3 rectal cancer: implications for local excision surgical strategies.

Belluco C, De Paoli A, Canzonieri V, Sigon R, Fornasarig M, Buonadonna A, Boz G, Innocente R, Perin T, Cossaro M, Polesel J, De Marchi F.

Ann Surg Oncol. 2011 Dec;18(13):3686-93. doi: 10.1245/s10434-011-1822-0. Epub 2011 Jun 21.

20.

Complete pathologic response following preoperative chemoradiation therapy for middle to lower rectal cancer is not a prognostic factor for a better outcome.

Pucciarelli S, Toppan P, Friso ML, Russo V, Pasetto L, Urso E, Marino F, Ambrosi A, Lise M.

Dis Colon Rectum. 2004 Nov;47(11):1798-807.

PMID:
15622571
Items per page

Supplemental Content

Write to the Help Desk